↓ Skip to main content

Dove Medical Press

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy

Overview of attention for article published in Biologics: Targets & Therapy, December 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#48 of 278)
  • Good Attention Score compared to outputs of the same age (76th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
96 Mendeley
Title
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
Published in
Biologics: Targets & Therapy, December 2018
DOI 10.2147/btt.s114530
Pubmed ID
Authors

Michelle E Keyel, C. Patrick Reynolds

Twitter Demographics

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 96 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 14%
Student > Doctoral Student 10 10%
Student > Bachelor 10 10%
Student > Master 9 9%
Other 7 7%
Other 16 17%
Unknown 31 32%
Readers by discipline Count As %
Medicine and Dentistry 20 21%
Biochemistry, Genetics and Molecular Biology 13 14%
Agricultural and Biological Sciences 10 10%
Immunology and Microbiology 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 11 11%
Unknown 35 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2022.
All research outputs
#4,356,616
of 23,577,654 outputs
Outputs from Biologics: Targets & Therapy
#48
of 278 outputs
Outputs of similar age
#95,139
of 439,980 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 4 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 278 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,980 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them